布洛芬钠（24 小时）的 IC50 值分别为 13 μM 和 370 μM，可抑制 COX-1 和 COX-2 的活性[1]。在 AGS 细胞（胃癌细胞系）中，500 μM 布洛芬钠持续 48 小时会导致细胞凋亡并抑制血管生成 [2]。在 AGS 细胞中，给予 500 μM 布洛芬钠超过 48 小时可抑制 Akt、VEGF-A、PCNA、Bcl2、OCT3/4 和 CD44 基因的转录，同时增加野生型 P53 和 Bax 基因的 RNA 水平 [2]。在囊性纤维化 (CF) 细胞模型和原代 CF 鼻上皮细胞中，布洛芬钠（500 μM，24 小时）可恢复微管重塑、微管依赖性细胞内胆固醇转运，并刺激微管迁移。外周细胞延伸[3]。通过光敏机制，布洛芬钠（500 μM，24 小时）可增加 MCF-7 和 MDA-MB-231 细胞中紫外线诱导的细胞死亡 [4]。

在产后乳腺癌模型中，布洛芬钠（在动物饲料中添加 300 毫克/千克，持续 14 天）可降低肿瘤总体生长并改善抗肿瘤免疫特性，而不会引起有害的自身免疫反应 [5]。在奥沙利铂诱导的慢性周围神经病变大鼠模型中，布洛芬钠（皮下注射，60 mg/kg，每隔一天一次，持续 15 天）可降低神经病变的风险[6]。口服布洛芬钠（20 mg/kg，每 12 小时一次，共 5 剂）会降低肌肉生长（平均肌纤维横截面积），同时使冈上肌腱对运动的适应不受影响 [7]。在慢性肺部感染的大鼠模型中，布洛芬钠（35 mg/kg，每天两次）可降低对铜绿假单胞菌的炎症反应[8]。

细胞活力测定 [2]
细胞类型： AGS 细胞
测试浓度： 100-1000 μM
孵育时间： 24 hrs（小时）、48 hrs（小时）
实验结果：抑制AGS细胞活力，IC50值为630 μM（台盼蓝染色，24 hrs（小时） （小时）））、456 μM（中性）红测定，24 小时）、549 μM（台盼蓝染色，48 小时）和 408 μM（中性红测定，48小时）。

Animal/Disease Models: PPBC syngeneic (D2A1) orthotopic Balb/c mouse model (postpartum) [5]
Doses: 300 mg/kg, daily for 14 days
Route of Administration: Feed with animal feed (add to crushed standard feed and Mix dry, then mix with water to form feed pellets and dry thoroughly)
Experimental Results: inhibit tumor growth, reduce the presence of immature monocytes and increase the number of T cells. Enhances Th1-related cytokines and promotes tumor border accumulation of T cells.

---

Animal/Disease Models: Oxaliplatin-induced peripheral neuropathy [6]
Doses: 60 mg/kg, once every other day for 15 days
Route of Administration: subcutaneous injection
Experimental Results: diminished sensory nerve conduction velocity (SNCV).

[1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7.
[2]. Hassan Akrami, et al. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015 May;36(5):3237-43.
[3]. Sharon M Rymut, et al. Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L317-27.
[4]. Emmanuelle Bignon, et al. Ibuprofen and ketoprofen potentiate UVA-induced cell death by a photosensitization process. Sci Rep. 2017 Aug 21;7(1):8885.
[5]. Nathan D Pennock, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer. 2018 Oct 1;6(1):98.
[6]. Thomas Krøigård, et al. Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy. Exp Brain Res. 2019 Oct;237(10):2645-2651.
[7]. Sarah Ilkhanipour Rooney, et al. Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. Am J Sports Med. 2016 Sep;44(9):2237-45.
[8]. M W Konstan, et al. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186-92.

C13H17O2-.NA+

228.26268

31121-93-4

Ibuprofen;15687-27-1;(S)-(+)-Ibuprofen;51146-56-6;(S)-(+)-Ibuprofen-d3;1329643-44-8;(R)-(-)-Ibuprofen;51146-57-7;Ibuprofen-d3 sodium;1219805-09-0;Ibuprofen-d3;121662-14-4

C(C1C=CC(C(C)C([O-])=O)=CC=1)C(C)C.[Na+]

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

H2O : ≥ 100 mg/mL (~438.10 mM)
DMSO : ~20.83 mg/mL (~91.26 mM)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。